Abstract:Background: The mortality rate of liver cancer ranks third in the world, and hepatocellular carcinoma (HCC) is a malignant tumor of the digestive tract. Cucurbitacin B (CuB), a natural compound extracted from Cucurbitaceae spp., is the main active component of Chinese patent medicine the Cucurbitacin Tablet, which has been widely used in the treatment of various malignant tumors in clinics, especially HCC. Purpose: This study explored the role and mechanism of CuB in the suppression of liver cancer progression. Methods: Cell Counting Kit -8 (CCK-8) and colony formation assays were used to detect the inhibitory function of CuB in Huh7, Hep3B, and Hepa1/6 hepatoma cells. Calcein-AM/propidium iodide (PI) staining and lactate dehydrogenase (LDH) measurement assays were performed to determine cell death. Mitochondrial membrane potential (Delta psi m) was measured, and flow cytometry was performed to evaluate cell apoptosis and cell cycle. Several techniques, such as proteomics, Western blotting (WB), and ribonucleic acid (RNA) interference, were utilized to explore the potential mechanism. The animal experiment was performed to verify the results of in vitro experiments. Results: CuB significantly inhibited the growth of Huh7, Hep3B, and Hepa1/6 cells and triggered the cell cycle arrest in G2/M phage without leading to cell death, especially apoptosis. Knockdown of insulin -like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of CuB, did not reverse CuB elicited cell cycle arrest. CuB enhanced phosphorylated ataxia telangiectasia mutated (p -ATM) and phosphorylated H2A histone family member X (gamma-H2AX) levels. Moreover, CuB increased p53 and p21 levels and decreased cyclin-dependent kinase 1 (CDK1) expression, accompanied by improving phosphorylated checkpoint kinase 1 (p-CHK1) level and suppressing cell division cycle 25C (CDC25C) protein level. Interestingly, these phenomena were partly abolished by a deoxyribonucleic acid (DNA) protector methylproamine (MPA). Animal studies showed that CuB also significantly suppressed tumor growth in BALB/c mice bearing Hepa1/6 cells. In tumor tissues, CuB reduced the expression levels of proliferating cell nuclear antigen (PCNA) and gamma-H2AX but did not change the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick -end labeling (TUNEL) level. Conclusion: This study demonstrated for the first time that CuB could effectively impede HCC progression by inducing DNA damage -dependent cell cycle arrest without directly triggering cell death, such as necrosis and apoptosis. The effect was achieved through ataxia telangiectasia mutated (ATM) -dependent p53-p21-CDK1 and checkpoint kinase 1 (CHK1)-CDC25C signaling pathways. These findings indicate that CuB may be used as an anti-HCC drug, when the current findings are confirmed by independent studies and after many more clinical phase 1, 2, 3, and 4 testings have been done.

Cucurbit[N]Urils (N=7,8) Binding of Camptothecin and the Effects on Solubility and Reactivity of the Anticancer Drug

Preparation and Solubility of the Camptothecin- Cucurbit（ N = 7 ）uril Solid Inclusion Complex

In Vitro and in Vivo Antitumor Activity of Cucurbitacin C, a Novel Natural Product from Cucumber

Influence of Cucurbit(n=7,8)uril on the Solubility and Stability of Chlorambucil

Investigation of Solubility of the Solid Inclusion Complexes Between Cucurbit (n =7) Uril and Camptothecin

What are the e ffects of cucurbit[n]uril on CTMS loading? Insights from QM calculations and MD simulations

Supramolecular Drug Inclusion Complex of Capecitabine with Cucurbit[7]uril and Inverted Cucurbit[7]uril

Host-guest interaction and properties of cucurbit[n]uril (n = 7,8) with chlorzoxazone

Host-Guest Complex of Cucurbituril with 5-Fluorouracil: Structural Study, Effect on Cytotoxicity, and Intracellular ROS Generation

The Construction of Cucurbit[7]uril-Based Supramolecular Nanomedicine for Glioma Therapy.

Supramolecular Combination Chemotherapy: Cucurbit[8]uril Complex Enhanced Platinum Drug Infiltration and Modified Nanomechanical Property of Colorectal Cancer Cells.

What are the effects of cucurbit[n]uril on CTMS loading? Insights from QM calculations and MD simulations

Toxicology and drug delivery by cucurbit[n]uril type molecular containers

Preparation and Biological Activity of Novel Cucurbit[8]uril–fullerene Complex

Host-Guest Interaction of Cucurbit[8]uril with N-(3-Aminopropyl)cyclohexylamine: Cyclohexyl Encapsulation Triggered Ternary Complex.

Orthogonal self-assembly of an organoplatinum(II) metallacycle and cucurbit[8]uril that delivers curcumin to cancer cells

Can functionalized cucurbituril bind actinyl cations efficiently? A density functional theory based investigation

Cytotoxicities of cucurbitacins from the stem bark of Aquilaria sinensis

Metabolic fate of the natural anticancer agent cucurbitacin B: an LC-MS/MS-enabled profiling of its major phase I and II conjugates in vivo

Cucurbitacin B Suppresses Hepatocellular Carcinoma Progression Through Inducing DNA Damage-Dependent Cell Cycle Arrest.

Evaluation of the Stability of Cucurbit[8]uril-Based Ternary Host−guest Complexation in Physiological Environment and the Fabrication of a Supramolecular Theranostic Nanomedicine